EBIT at other companies
Other financials
Where this comes from
Calculated from ARS Pharmaceuticals, Inc.’s reported figures.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s EBIT?
- ARS Pharmaceuticals, Inc. (SPRY) reported EBIT of -$60.15M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s EBIT changed year-over-year?
- ARS Pharmaceuticals, Inc.'s EBIT decreased by 61.8% year-over-year, from -$37.18M to -$60.15M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s EBIT?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s EBIT has grown at a 71.6% compound annual growth rate (CAGR), from -$35.52M to -$179.45M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.